Clinical study of Qiming granule combined with compound anisodine injection in the treatment of diabetic retinopathy

Objective:To investigate the clinical study of Qiming granule combined with compound anisodine injection in the treatment of diabetic retinopathy.Methods:104 patients with nonproliferative diabetic retinopathy admitted to department of ophthalmology in Xishui Hospital Affiliated to Hubei University of science and technology from September 2016 to May 2018 were selected as the study subjects.According to the principle of treatment,they were divided into 52 cases in the control group and 52 cases in the treatment group,the clinical efficacy,blood sugar and lipid levels,hemorheological changes and adverse reactions were compared between the two groups.Results:The total effective rate difference between the treatment group(92.31%)and the control group(71.15%)was statistically significant(χ^(2)=7.792,P=0.005).After treatment,the two groups of fasting plasma glucose(FPG),hemoglobin A1c(HbA1c),total cholesterol(TC),low density lipoprotein-cholesterol(LDL-C),whole blood high-viscosity,whole blood cut viscosity,whole blood low-cut viscosity,plasma viscosity,number of microangioma and area of the hemorrhage were significantly lower than before treatment(P<0.05),and the levels of FPG,HbA1c,TC,LDL-C,whole blood highviscosity,whole blood cut viscosity,whole blood low-cut viscosity,plasma viscosity,number of microangioma and area of the hemorrhage in the treatment group were significantly lower than those in the control group(χ^(2)=0.122,P=0.727).Conclusions:Qiming granule combined with compound anisodine injection can effectively improve the clinical efficacy of patients with non-proliferative DR,and its mechanism may be related to improve blood sugar and blood lipid levels and correct blood rheology disorder,reduce microangioma and hemorrhage.It has clinical promotion significance.

Neuroprotective Effect of Compound Anisodine in a Mouse Model with Chronic Ocular Hypertension

Background：Compound anisodine （CA） is a compound preparation made from hydrobromide anisodine and procaine hydrochloride.The former is an M-choline receptor blocker with the function of regulating the vegetative nervous system,improving microcirculation,and so on.The latter is an antioxidant with the activities ofneuroprotection.This study aimed to investigate the potential neuroprotection of CA,which affects the degeneration of the retinal ganglion cells （RGCs） in an animal model with chronic ocular hypertension.Methods：Female C57BL/6J mice （n =24） were divided randomly into four groups：Normal control group without any treatment （Group A,n =6）;CA control group with feeding the CA solution （Group B,n =6）;microbeads （MBs） control group with injecting MB into the anterior chamber （Group C,n =6）;CA study group with MB injection and with feeding the CA solution （Group D,n =6）.Intraocular pressure （IOP） was measured every 3 days after MB injection.At the 21st day,neurons were retrograde-labeled by Fluoro-Gold （FG）.Animals were sacrificed on the 27th day.Retinal flat mounts were stained immunohistologically by β-Ⅲ-tubulin.FG-retrograde-labeled RGCs,β-Ⅲ-tubulin-positive RGCs,and β-Ⅲ-tubulin-positive nerve fibers were quantified.Results：Mice of Groups C and D expressed the incidence of consistent IOP elevation,which is above the IOP level of Group A with the normal one.There is no significant difference in IOP between Groups A and B （P ＞ 0.05）.On the 27th day,there were distinct loss in stained RGCs and nerve fibers from Groups C and D compared with Group A （all P ＜ 0.00l）.The quantity was significantly higher in Group D as compared to Group C （all P ＜ 0.00l） but lower than Group A （all P ＜ 0.001）.There was no significant difference in the quantity of RGCs and nerve fibers between Groups A and B （all P ＞ 0.05）.Conclusions：These findings suggest that CA plays an importantly neuroprotective role on RGCs in a mouse model with chronic ocular hypertension.